246 related articles for article (PubMed ID: 21822297)
1. Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy.
Nguyen-Pham TN; Yang DH; Nguyen TA; Lim MS; Hong CY; Kim MH; Lee HJ; Lee YK; Cho D; Bae SY; Ahn JS; Kim YK; Chung IJ; Kim HJ; Lee JJ
Cell Mol Immunol; 2012 Jan; 9(1):45-53. PubMed ID: 21822297
[TBL] [Abstract][Full Text] [Related]
2. Natural killer-dendritic cell cross-talk in cancer immunotherapy.
Kalinski P; Mailliard RB; Giermasz A; Zeh HJ; Basse P; Bartlett DL; Kirkwood JM; Lotze MT; Herberman RB
Expert Opin Biol Ther; 2005 Oct; 5(10):1303-15. PubMed ID: 16197336
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist.
Pham TN; Hong CY; Min JJ; Rhee JH; Nguyen TA; Park BC; Yang DH; Park YK; Kim HR; Chung IJ; Kim HJ; Lee JJ
Exp Mol Med; 2010 Jun; 42(6):407-19. PubMed ID: 20386085
[TBL] [Abstract][Full Text] [Related]
4. Helper activity of natural killer cells during the dendritic cell-mediated induction of melanoma-specific cytotoxic T cells.
Wong JL; Mailliard RB; Moschos SJ; Edington H; Lotze MT; Kirkwood JM; Kalinski P
J Immunother; 2011 Apr; 34(3):270-8. PubMed ID: 21389871
[TBL] [Abstract][Full Text] [Related]
5. Potency of Both Human Th1 and NK Helper Cell Activation is Determined by IL-12p70-Producing PAMP-Matured DCs.
Oth T; Van Elssen CH; Schnijderberg MC; Senden-Gijsbers BL; Germeraad WT; Bos GM; Vanderlocht J
J Interferon Cytokine Res; 2015 Sep; 35(9):748-58. PubMed ID: 26134473
[TBL] [Abstract][Full Text] [Related]
6. CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.
Lichtenegger FS; Mueller K; Otte B; Beck B; Hiddemann W; Schendel DJ; Subklewe M
PLoS One; 2012; 7(9):e44266. PubMed ID: 22962607
[TBL] [Abstract][Full Text] [Related]
7. Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells.
Schnurr M; Scholz C; Rothenfusser S; Galambos P; Dauer M; Röbe J; Endres S; Eigler A
Cancer Res; 2002 Apr; 62(8):2347-52. PubMed ID: 11956095
[TBL] [Abstract][Full Text] [Related]
8. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
9. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
10. Generation of mature dendritic cells fully capable of T helper type 1 polarization using OK-432 combined with prostaglandin E(2).
Sato M; Takayama T; Tanaka H; Konishi J; Suzuki T; Kaiga T; Tahara H
Cancer Sci; 2003 Dec; 94(12):1091-8. PubMed ID: 14662025
[TBL] [Abstract][Full Text] [Related]
11. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075.
Spranger S; Javorovic M; Bürdek M; Wilde S; Mosetter B; Tippmer S; Bigalke I; Geiger C; Schendel DJ; Frankenberger B
J Immunol; 2010 Jul; 185(1):738-47. PubMed ID: 20511554
[TBL] [Abstract][Full Text] [Related]
12. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses.
Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA
Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function.
Mailliard RB; Son YI; Redlinger R; Coates PT; Giermasz A; Morel PA; Storkus WJ; Kalinski P
J Immunol; 2003 Sep; 171(5):2366-73. PubMed ID: 12928383
[TBL] [Abstract][Full Text] [Related]
14. Third generation dendritic cell vaccines for tumor immunotherapy.
Frankenberger B; Schendel DJ
Eur J Cell Biol; 2012 Jan; 91(1):53-8. PubMed ID: 21439674
[TBL] [Abstract][Full Text] [Related]
15. Activated natural killer cell-mediated immunity is required for the inhibition of tumor metastasis by dendritic cell vaccination.
Kim A; Noh YW; Kim KD; Jang YS; Choe YK; Lim JS
Exp Mol Med; 2004 Oct; 36(5):428-43. PubMed ID: 15557815
[TBL] [Abstract][Full Text] [Related]
16. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
17. Immunological Characterization of Whole Tumour Lysate-Loaded Dendritic Cells for Cancer Immunotherapy.
Rainone V; Martelli C; Ottobrini L; Biasin M; Texido G; Degrassi A; Borelli M; Lucignani G; Trabattoni D; Clerici M
PLoS One; 2016; 11(1):e0146622. PubMed ID: 26795765
[TBL] [Abstract][Full Text] [Related]
18. In-Depth Analysis of the Impact of Different Serum-Free Media on the Production of Clinical Grade Dendritic Cells for Cancer Immunotherapy.
Calmeiro J; Mendes L; Duarte IF; Leitão C; Tavares AR; Ferreira DA; Gomes C; Serra J; Falcão A; Cruz MT; Carrascal MA; Neves BM
Front Immunol; 2020; 11():593363. PubMed ID: 33613517
[TBL] [Abstract][Full Text] [Related]
19. Human natural killer cells exposed to IL-2, IL-12, IL-18, or IL-4 differently modulate priming of naive T cells by monocyte-derived dendritic cells.
Agaugué S; Marcenaro E; Ferranti B; Moretta L; Moretta A
Blood; 2008 Sep; 112(5):1776-83. PubMed ID: 18579793
[TBL] [Abstract][Full Text] [Related]
20. Polarization of naive T cells into Th1 or Th2 by distinct cytokine-driven murine dendritic cell populations: implications for immunotherapy.
Feili-Hariri M; Falkner DH; Morel PA
J Leukoc Biol; 2005 Sep; 78(3):656-64. PubMed ID: 15961574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
